With HNSCC driven by EGFR aberrations, all three CDX models exhibited sustained tumor growth control by TAVO412 even after treatment cessation (Figure 1B, Supplementary Table 1). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.